After factoring in JD HEALTH (06618.HK) +0.320 (+0.658%) Short selling $77.28M; Ratio 154.143% 's 2025 results data, Morgan Stanley has raised its 2026-28 revenue forecasts for JD HEALTH (06618.HK) +0.320 (+0.658%) Short selling $77.28M; Ratio 154.143% by 5%/ 6%/ 7% to reflect the continued growth momentum in online pharmaceutical sales.In Morgan Stanley's estimate, JD HEALTH's 2026 revenue growth will rise by 18%, in which pharmaceutical sales, non-pharmaceutical sales, and service income will increase by 25%, 12%, and 19% YoY.In terms of earnings, Morgan Stanley predicts JD HEALTH's 2026 adjusted operating profit to remain flat. It has cut the 2026-28 adjusted EPS forecasts by 4%/ 5%/ 6%.Morgan Stanley's target price for JD HEALTH has fallen from HKD70 to HKD66.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)
AASTOCKS Financial News